- Home
- VBIX vs CELU Comparison
VBIX vs CELU Comparison
Compare VBIX & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VBIX
- CELU
- Stock Information
- Founded
- VBIX N/A
- CELU 2016
- Country
- VBIX Israel
- CELU United States
- Employees
- VBIX N/A
- CELU N/A
- Industry
- VBIX Computer Software: Prepackaged Software
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- VBIX Technology
- CELU Health Care
- Exchange
- VBIX Nasdaq
- CELU Nasdaq
- Market Cap
- VBIX 44.0M
- CELU 49.8M
- IPO Year
- VBIX N/A
- CELU N/A
- Fundamental
- Price
- VBIX $4.49
- CELU $1.75
- Analyst Decision
- VBIX
- CELU
- Analyst Count
- VBIX 0
- CELU 0
- Target Price
- VBIX N/A
- CELU N/A
- AVG Volume (30 Days)
- VBIX 43.4K
- CELU 73.3K
- Earning Date
- VBIX 08-14-2025
- CELU 05-08-2025
- Dividend Yield
- VBIX N/A
- CELU N/A
- EPS Growth
- VBIX N/A
- CELU N/A
- EPS
- VBIX N/A
- CELU N/A
- Revenue
- VBIX $19,672,000.00
- CELU $54,220,000.00
- Revenue This Year
- VBIX N/A
- CELU $23.29
- Revenue Next Year
- VBIX N/A
- CELU N/A
- P/E Ratio
- VBIX N/A
- CELU N/A
- Revenue Growth
- VBIX N/A
- CELU 138.11
- 52 Week Low
- VBIX $0.18
- CELU $1.00
- 52 Week High
- VBIX $12.00
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- VBIX N/A
- CELU 42.55
- Support Level
- VBIX N/A
- CELU $1.78
- Resistance Level
- VBIX N/A
- CELU $2.10
- Average True Range (ATR)
- VBIX 0.00
- CELU 0.19
- MACD
- VBIX 0.00
- CELU -0.07
- Stochastic Oscillator
- VBIX 0.00
- CELU 4.00
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.